Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Authors
Keywords
Dopamine Agonist, Memantine, Amantadine, Rasagiline, Motor Fluctuation
Journal
CNS DRUGS
Volume 28, Issue 12, Pages 1155-1184
Publisher
Springer Nature
Online
2014-10-24
DOI
10.1007/s40263-014-0205-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The acute brain response to levodopa heralds dyskinesias in Parkinson disease
- (2014) Damian M. Herz et al. ANNALS OF NEUROLOGY
- Inhibition of Adenylyl Cyclase Type 5 Prevents L-DOPA-Induced Dyskinesia in an Animal Model of Parkinson's Disease
- (2014) H.-Y. Park et al. JOURNAL OF NEUROSCIENCE
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease
- (2014) Danhui Zhang et al. MOVEMENT DISORDERS
- Effect of nicotine on l-dopa-induced dyskinesia in animal models of Parkinson’s disease: a systematic review and meta-analysis
- (2014) Cheng-long Xie et al. NEUROLOGICAL SCIENCES
- Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease
- (2014) J. Y. Hong et al. NEUROLOGY
- Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease
- (2014) Christopher Kobylecki et al. PARKINSONISM & RELATED DISORDERS
- Functional interaction between pre-synaptic α6β2-containing nicotinic and adenosine A2Areceptors in the control of dopamine release in the rat striatum
- (2013) P Garção et al. BRITISH JOURNAL OF PHARMACOLOGY
- Nicotinic receptors regulate the dynamic range of dopamine release in vivo
- (2013) Jessica L. Koranda et al. JOURNAL OF NEUROPHYSIOLOGY
- Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency
- (2013) Roser Pons et al. MOVEMENT DISORDERS
- Quantitative wearable sensors for objective assessment of Parkinson's disease
- (2013) Walter Maetzler et al. MOVEMENT DISORDERS
- Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
- (2013) Stewart A. Factor et al. MOVEMENT DISORDERS
- Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
- (2013) Rupam Borgohain et al. MOVEMENT DISORDERS
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
- (2013) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
- (2013) C. Warren Olanow et al. MOVEMENT DISORDERS
- Which dyskinesia scale best detects treatment response?
- (2013) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
- (2013) Erwan Bezard et al. MOVEMENT DISORDERS
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: Clinical features and mechanisms
- (2013) Sara Pietracupa et al. PARKINSONISM & RELATED DISORDERS
- Perampanel in Parkinson Disease Fluctuations
- (2012) Olivier Rascol et al. CLINICAL NEUROPHARMACOLOGY
- Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
- (2012) Susan Duty CNS DRUGS
- Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease
- (2012) A. H. V. Schapira et al. EUROPEAN JOURNAL OF NEUROLOGY
- Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
- (2012) J. J. Ferreira et al. EUROPEAN JOURNAL OF NEUROLOGY
- Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study
- (2012) C. Moreau et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
- (2012) P. A. LeWitt et al. NEUROLOGY
- Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial
- (2012) O. Rascol et al. PARKINSONISM & RELATED DISORDERS
- Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
- (2011) Imtiaz Ahmed et al. BRAIN
- Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesia
- (2011) K. Elisabet Ohlin et al. BRAIN
- The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias
- (2011) Christopher A. Lieu et al. BRAIN RESEARCH BULLETIN
- Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
- (2011) Kristin B. Dupre et al. EXPERIMENTAL NEUROLOGY
- Changes in the mRNA Levels of α2A and α2C Adrenergic Receptors in Rat Models of Parkinson’s Disease and l-DOPA-Induced Dyskinesia
- (2011) Amal Alachkar et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
- (2011) Mahmoud M. Iravani et al. JOURNAL OF NEURAL TRANSMISSION
- Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia
- (2011) Nina Nevalainen et al. JOURNAL OF NEUROCHEMISTRY
- Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning
- (2011) Adjmal Nahimi et al. JOURNAL OF NEUROCHEMISTRY
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease
- (2011) Andrew Lees et al. MOVEMENT DISORDERS
- Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease
- (2011) Rebecca Stowe et al. MOVEMENT DISORDERS
- A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
- (2011) Kitty K. Wong et al. MOVEMENT DISORDERS
- Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials
- (2011) Cristina Sampaio et al. MOVEMENT DISORDERS
- A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
- (2011) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio
- (2011) Marios Politis et al. MOVEMENT DISORDERS
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
- (2011) Susan H. Fox et al. MOVEMENT DISORDERS
- Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia
- (2011) Bernardino Ossola et al. NEUROPHARMACOLOGY
- Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia
- (2011) M. Carta et al. NEUROSCIENCE
- The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys
- (2011) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
- (2011) Emmanuelle Pourcher et al. PARKINSONISM & RELATED DISORDERS
- Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats
- (2011) Christopher J. Barnum et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
- (2011) Hideyuki Sawada et al. PLoS One
- Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
- (2011) Véronique Sgambato-Faure et al. PROGRESS IN NEUROBIOLOGY
- Sustained-release Madopar HBS® compared with standard Madopar® in the long-term treatment of de novo parkinsonian patients
- (2010) E. Dupont et al. ACTA NEUROLOGICA SCANDINAVICA
- Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia
- (2010) Daniella Rylander et al. ANNALS OF NEUROLOGY
- mTORC1 signaling in Parkinson disease and L-DOPA-induced dyskinesia: A sensitized matter
- (2010) Emanuela Santini et al. CELL CYCLE
- Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats
- (2010) Yoshihiro Tani et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets
- (2010) K. Tayarani-Binazir et al. EXPERIMENTAL NEUROLOGY
- Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
- (2010) Robert A. Hodgson et al. EXPERIMENTAL NEUROLOGY
- Dopamine D1-histamine H3Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway
- (2010) Estefanía Moreno et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial
- (2010) Martin Wolz et al. JOURNAL OF NEURAL TRANSMISSION
- Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease
- (2010) Christopher Kobylecki et al. JOURNAL OF NEUROCHEMISTRY
- Pharmacokinetics of levodopa
- (2010) Manuela Contin et al. JOURNAL OF NEUROLOGY
- Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
- (2010) T. H. Johnston et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Nicotinic Receptor-Mediated Reduction in L-DOPA-Induced Dyskinesias May Occur via Desensitization
- (2010) T. Bordia et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
- (2010) Paolo Calabresi et al. LANCET NEUROLOGY
- Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
- (2010) Murat Emre et al. LANCET NEUROLOGY
- Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
- (2010) Juliana Bronzova et al. MOVEMENT DISORDERS
- Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease
- (2010) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
- (2010) Elisabeth Wolf et al. MOVEMENT DISORDERS
- Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease
- (2010) P. Stathis et al. MOVEMENT DISORDERS
- The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
- (2010) Tom H. Johnston et al. MOVEMENT DISORDERS
- Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets
- (2010) Louisa Clare Johnston et al. MOVEMENT DISORDERS
- Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
- (2010) Ray L. Watts et al. MOVEMENT DISORDERS
- Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study
- (2010) Karla Eggert et al. MOVEMENT DISORDERS
- Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease
- (2010) Manolo Carta et al. MOVEMENT DISORDERS
- Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia
- (2010) Bai-Yun Zeng et al. NEUROBIOLOGY OF DISEASE
- Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease
- (2010) Sylvia Navailles et al. NEUROBIOLOGY OF DISEASE
- Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys
- (2010) Nicolas Morin et al. NEUROPHARMACOLOGY
- Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys
- (2010) Christopher A. Lieu et al. PARKINSONISM & RELATED DISORDERS
- Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia
- (2010) Emanuela Santini et al. PLoS One
- Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants
- (2010) M. Politis et al. Science Translational Medicine
- Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation
- (2009) Sanja Darmopil et al. BIOLOGICAL PSYCHIATRY
- Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease
- (2009) Karla Eggert et al. CLINICAL NEUROPHARMACOLOGY
- Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model
- (2009) Ana Muñoz et al. EXPERIMENTAL NEUROLOGY
- Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets
- (2009) K.A. Stockwell et al. EXPERIMENTAL NEUROLOGY
- Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson’s: anin vivoimaging study
- (2009) Vesna Sossi et al. JOURNAL OF NEUROCHEMISTRY
- l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia
- (2009) Hanna S. Lindgren et al. JOURNAL OF NEUROCHEMISTRY
- Pharmacological Analysis Demonstrates Dramatic Alteration of D1 Dopamine Receptor Neuronal Distribution in the Rat Analog of L-DOPA-Induced Dyskinesia
- (2009) A. Berthet et al. JOURNAL OF NEUROSCIENCE
- Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
- (2009) D. Rylander et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Prominent Role of 3/ 6 2* nAChRs in Regulating Evoked Dopamine Release in Primate Putamen: Effect of Long-Term Nicotine Treatment
- (2009) X. A. Perez et al. MOLECULAR PHARMACOLOGY
- Onset and spread of dyskinesias and motor symptoms in Parkinson's disease
- (2009) Giovanni Fabbrini et al. MOVEMENT DISORDERS
- NMDA antagonist memantine improves levodopa-induced dyskinesias and “On-off” phenomena in Parkinson's disease
- (2009) Sara Varanese et al. MOVEMENT DISORDERS
- Metabotropic glutamate receptor type 5 in levodopa-induced motor complications
- (2009) Bazoumana Ouattara et al. NEUROBIOLOGY OF AGING
- Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides
- (2009) Mohamed Khalil Tamim et al. NEUROPHARMACOLOGY
- Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease
- (2009) Hanna S Lindgren et al. NEUROPSYCHOPHARMACOLOGY
- Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease
- (2009) Angelo Antonini et al. PARKINSONISM & RELATED DISORDERS
- Rodent models of treatment-induced motor complications in Parkinson's disease
- (2009) M. Angela Cenci et al. PARKINSONISM & RELATED DISORDERS
- Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors
- (2009) Ripple Talati et al. PARKINSONISM & RELATED DISORDERS
- From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease
- (2009) Peter Jenner PARKINSONISM & RELATED DISORDERS
- Adenosine, adenosine A2A antagonists, and Parkinson's disease
- (2009) P. Jenner et al. PARKINSONISM & RELATED DISORDERS
- The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats
- (2009) Karen L. Eskow et al. SYNAPSE
- Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate
- (2009) Monty A. Silverdale et al. SYNAPSE
- Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
- (2008) Peter A. LeWitt et al. ANNALS OF NEUROLOGY
- Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
- (2008) A. Munoz et al. BRAIN
- BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease
- (2008) T Foltynie et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Dichotomous Anatomical Properties of Adult Striatal Medium Spiny Neurons
- (2008) T. S. Gertler et al. JOURNAL OF NEUROSCIENCE
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- Pharmacokinetics and pharmacodynamics of levodopa
- (2008) John G. Nutt MOVEMENT DISORDERS
- Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
- (2008) Pedro J. García Ruiz et al. MOVEMENT DISORDERS
- Placebo influences on dyskinesia in Parkinson's disease
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
- (2008) György Haskó et al. NATURE REVIEWS DRUG DISCOVERY
- PET demonstrates reduced dopamine transporter expression in PD with dyskinesias
- (2008) A. R. Troiano et al. NEUROLOGY
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
- Role of receptor heterodimers in the development of l-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease
- (2008) Chiara Fiorentini et al. PARKINSONISM & RELATED DISORDERS
- Priming for l-dopa-induced dyskinesia in Parkinson’s disease: A feature inherent to the treatment or the disease?
- (2008) Agnès Nadjar et al. PROGRESS IN NEUROBIOLOGY
- mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys
- (2007) Pershia Samadi et al. NEUROBIOLOGY OF AGING
- l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
- (2007) Barbara Picconi et al. NEUROBIOLOGY OF DISEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now